DOCSLIB.ORG

Burkholderia (B

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ALX-009 A promising antimicrobial therapy for Cystic Fibrosis Non confidential presentation 08.09.2014 About Alaxia Founded in 2008, 1st Product: ALAXIA is a private biotech company based in Lyon (France) Incorporated into Stragen Group in 2011 ALX-009 OSCN-/Lactoferrin Strong scientific background in respiratory (Cystic Fibrosis, respiratory tract infections…) a promising antimicrobial Main focus: medication Development of medicinal products for the treatment of Cystic targeting respiratory diseases Fibrosis based on our Peroxidase platform Non confidential presentation 2 Presentation Overview Disease overview Scientific rationale and Mode of Action Preclinical overview (antimicrobial) Conclusion Recommended reading Non confidential presentation 3 Cystic Fibrosis The most common orphan disease in Caucasians Genetic autosomal recessive disease Prevalence: 1 / 10000 100 000 patients (EU + US) Chronic, progressive and lethal due to emergence of multiresistant bacteria Life expectancy < 35 y 2 hours of care per day Non confidential presentation 4 Physiopathology Genetic disease of the body’s mucus glands Affects the respiratory and digestive systems Implication of Cftr* gene – CFTR Protein Cftr Dysfunctional Defective Gene Airway CFTR Mutation Environment *CFTR: Cystic Fibrosis Transmembrane conductance Regulator Non confidential presentation 5 Main pathogens in Cystic Fibrosis patient lung Opportunistic bacteria Staphylococcus (S. aureus) Pseudomonas (P. aeruginosa) Burkholderia (B. cepacia complex (BCC)) Lung Mycobacterium (M. abscessus) Stenotrophomonas (S. maltophilia) Inflammation Fungi FEV1 Aspergillus (A. fumigatus) Viruses Influenza Non confidential presentation 6 Main pathogens in Cystic Fibrosis patient lungs Germs Found in the Lungs of People with CF by Age, 2012 CFF. Annual Report 2012. Non confidential presentation 7 Scientific and Medical Rationale In CF patients SCN- hypothesis Airway Surface LPO 1. Defective/absent CFTR Liquid SCN- OSCN- CF CELL - (ASL) Impaired SCN transport H2O2 Adapted from Fisher, 2009 2. Defective Lactoperoxidase system DUOX Decreased OSCN- level in lower airways CFTR 3. Decreased Lactoferrin level/activity A Ciliated cells ALX-009 (OSCN- + bLF) by inhalation ALX-009 compensates defective Thick mucus host protection against microorganisms + defective and provides to CF patients a mucociliary therapeutic option to fight lung infections. clearance Potentially breaking the vicious circle leading to lethal conditions Non confidential presentation 8 Healthy airway epithelium Bacteria 60 µm/s OSCN- Lactoperoxidase SCN- Lactoferrin MUCUS H2O2 O2 CILIA CFTR DUOX - - - - (SCN , Cl , I , HCO3 ) Mucin CILIATED BASAL GOBLET CILIATED BASAL GOBLET CELLS CELLS CELS CELLS CELLS CELS Lactoperoxidase Lactoferrin Overview of airway epithelial cells and glands SUBMUCOSAL GLANDS Non confidential presentation 9 Cystic fibrosis airway epithelium Bacteria - OSCN 0 µm/s Biofilm Lactoperoxidase Lactoferrin MUCUS H2O2 O2 CILIA SCN- DUOX CFTR CILIATED BASAL GOBLET CILIATED BASAL GOBLET CELLS CELLS CELS CELLS CELLS CELS Lactoperoxidase Lactoferrin Overview of airway epithelial cells and glands SUBMUCOSAL GLANDS Non confidential Non confidential presentation 10 ALX-009: an innovative approach OSCN- + Lactoferrin Balance defective innate host immune system Treatment of lung infection Non confidential presentation 11 ALX-009 Association of two key endogenous substances for innate immune response against infections LACTOFERRIN OSCN- Extracted from Enzymatic extemporaneous milk production Non confidential presentation 12 OSCN-: Mode of Action* NX040764341JB Oxidation of free sulfhydryl resulting in disulfide bridges Selective Detoxification Of -SH Reaction Hypothiocyanite By Mammalian HOSCN with amino acids OSCN- (Trp, His, Tyr) Thioredoxin HS- Reductase, The Missing Link In Lung Innate Immunity And Antioxidant Defense Inactivation of metabolic bacterial key enzymes Bacterial glycolysis inhibition (glyceraldehyde 3-P dehydrogenase, hexokinase…) Carlson et al. Infection and immunity. 1984, 44, 581-586 Mickelson, M. N. J. et al. Gen.Microbiol. 1966, 43, 31-43 Bacteriostatic and bactericidal effect Safe for the host Selective Detoxification Of Hypothiocyanite By Mammalian Thioredoxin Reductase, The Missing Link In Lung Innate Immunity And Antioxidant Defense Chandler et al. ATS conference 2013 . Non confidential presentation 13 * Literature data Lactoferrin: Mode of Action* IRON SEQUESTRATION MOLECULAR ANTIOXIDANT INTERACTIONS Binds heavy metals that catalyze oxidation reactions ANTIBACTERIAL (fatty acids) Deconstructs membranes ANTIBACTERIAL Binds iron essential ANTIVIRAL to bacterial growth Prevents entry of virus into host cells by binding to virus or cells receptors GLOBULAR PROTEIN ANTI-INFLAMMATORY Reduces production of EMULSIFIYING TNFα IL-1β IL-6 IL-8 LACTOFERRIN Surfactant * Literature data Non confidential presentation 14 ALX-009 Preclinical data OSCN- LACTOFERRIN Able to disrupt biofilms and to prevent its formation Effective against Gram+ and Gram- bacteria Preliminary evidence indicates that ALX-009 may have the potential to compensate and Biofilm to restart peroxidase system with OSCN- production using endogenous H O Peroxidase 2 2 OSCN- Pseudomonas H2O2 O2 CFTR Respiratory tract SCN- DUOX Airway epithelium Non confidential presentation 15 Target Unmet Medical Need in CF Burkholderia infections EMA/CHMP opinion in Orphan drug designation report interest “The product has a different antimicrobial mechanism of action compared to antibiotics. With regard to significant benefit, a very important point is that Meveol can act on Burkholderia cepacia. Authorised inhaled products target Gram negative only, excluding Burkholderia cepacia indeed. …. Burkholderia cepacia, which was used in in vitro studies in this application, is one of these bacteria” Non confidential 16 Burkholderia cepacia antibiotic sensibility Bcc is resistant to antibiotics available for CF management Susceptibilities of 66 B. cepacia strains to 11 antibiotics determined by the agar dilution method a MIC (µg/ml) % Strains ANTIBIOTIC 50% 90% Range S I R Piperacillin 32 >128 2 - >128 38 24 38 Ceftazidime 8 32 1 - >64 42 46 12 Imipenem 16 64 4 - >64 1 10 89 Meropenem 4 8 1 - 16 67 27 6 Temocillin 8 32 2 - 64 82 - 18 Sulbactam >64 >64 4 - >64 ND ND ND Ciprofloxacin 16 64 1 - >64 6 9 85 Rifampin 64 >64 32 - >64 0 0 100 TMP-SMZ 2/38 8/152 0.25/4 - >8/152 62 - 38 Minocycline 8 64 0.5 - 64 47 17 36 Tobramycin >64 >64 >64 0 0 100 Bonacorsi et al., Antimicro Agents Chemoth. 43(2):213-7. Non confidential presentation 17 Burkholderia cepacia complex in the clinic Rapid decline of lung function Cepacia Syndrome: syndrome at high risk for fatal outcome from respiratory failure Segregation of Burkholderia positive patients from other CF patients Patients are not eligible for antibiotic clinical trials Lung transplantation is compromised/not possible The aim of following study is to test the efficacy of ALX-009 on clinical Bcc strains Non confidential presentation 18 Test efficacy of ALX-009 by Checkboard method Isolates were challenged with bLF and OSCN- alone or in combination. Assays were done according to the CLSI M07-A9 guideline. Lactoferrin Checkboard to measure products interaction. OSCN ALX-009 Non confidential presentation 19 Origin of 155 isolates from CF patients tested 2% EU 13% US 23% Canada 62% South America Non confidential presentation 20 Origin of 155 isolates from CF patients tested GENOMOVAR Proportion tested in Alaxia Prevalence in CF* I 6.35 % 3 % II 30.95 % 37 % III 31.75 % 31 % IV 8.73 % <3 % V 4.76 % 5 % VI 7.14 % 3 % VII 1.59 % VIII 0.79 % <3 % IX 0 % Other Bcc strains 7.94 % *LiPuma et al., 2011 40% 30% 20% 10% 0% I II III IV V VI VII VII IX Other Non confidential presentation 21 OSCN-/bLF (ALX-009) combination is able to inhibit the growth of 100% of the 155 tested clinical isolates* bLF decreases up to 40% the concentration of OSCN- required to inhibit growth when assayed alone (MIC value) 8% of combinations were synergistic and 58% were additive *Representative of clinical Bcc species Presented Burkholderia International Working group congress – 2014 Poster CF Congress – Atlanta - 2014 22 TIME KILL CURVES Figure 4: Trend curves from mean CFU values from 14 Bcc clinical isolates, selected from their low, medium or high susceptibility to OSCN- and/or bLF. Bcc Biofilm – On going Non confidential 24 Bcc only ? Non confidential 25 Efficacy against Pseudomonas aeruginosa CFU counts of Pseudomonas aeruginosa IN VIVO TESTS After treatment or not with OSCN- / bLF infection inoculum 106 CFU Demonstration of efficacy on female mice, previously infected with mucoïd count Pseudomonas aeruginosa strain isolated CFU from CF Patients CER - Unpublished Animal received intra-tracheal ALX-009 injection treatment at 24h and 48h post infection. Bacterial counts were performed at 72h post infection Non confidential presentation 26 Efficacy against Pseudomonas aeruginosa biofilms Dartmouth Medical School 1,E+10 NH 1,E+08 Synergy with tobramycin (Tb) 1,E+06 CFU/ml 1,E+04 1595 non mucoid 1587 non mucoid 1596 non mucoid 1,E+02 5451 Mucoid 1,E+00 1585 Mucoid NACFC – Orlando 2012 5450 Mucoid Non confidential presentation 27 Wide spectrum of efficacy* Achromobacter Xylosoxidans Legionella spp Aeromonas hydrophila Listeria monocytogenes (Gram+) Bacillus brevis, Bacillus cereus (Gram+) Mycobacterium abscessus, M. smegmatis, M. tuberculosis Bacillus megaterium, Bacillus anthracis (Gram+) Neisseria spp BACTERIA Burkholderia cepacia complex Pseudomonas aeruginosa
Recommended publications
  • Shigella Infection - Factsheet

    Shigella Infection - Factsheet

    Shigella Infection - Factsheet What is Shigellosis? How common is it? Shigellosis is an infectious disease caused by a group of bacteria (germs) called Shigella. It’s also known as bacillary dysentery. There are four main types of Shigella germ but Shigella sonnei is by far the commonest cause of this illness in the UK. Most cases of the other types are usually brought in from abroad. How is Shigellosis caught? Shigella is not known to be found in animals so it always passes from one infected person to the next, though the route may be indirect. Here are some possible ways in which you can get infected: • Shigella germs are present in the stools of infected persons while they are ill and for a week or two afterwards. Most Shigella infections are the result of germs passing from stools or soiled fingers of one person to the mouth of another person. This happens when basic hygiene and hand washing habits are inadequate, such as in young toddlers who are not yet fully toilet trained. Family members and playmates of such children are at high risk of becoming infected. • Shigellosis can be acquired from someone who is infected but has no symptoms. • Shigellosis may be picked up from eating contaminated food, which may look and smell normal. Food may become contaminated by infected food handlers who do not wash their hands properly after using the toilet. They should report sick and avoid handling food if they are ill but they may not always have symptoms. • Vegetables can become contaminated if they are harvested from a field with sewage in it.
  • Succession and Persistence of Microbial Communities and Antimicrobial Resistance Genes Associated with International Space Stati

    Succession and Persistence of Microbial Communities and Antimicrobial Resistance Genes Associated with International Space Stati

    Singh et al. Microbiome (2018) 6:204 https://doi.org/10.1186/s40168-018-0585-2 RESEARCH Open Access Succession and persistence of microbial communities and antimicrobial resistance genes associated with International Space Station environmental surfaces Nitin Kumar Singh1, Jason M. Wood1, Fathi Karouia2,3 and Kasthuri Venkateswaran1* Abstract Background: The International Space Station (ISS) is an ideal test bed for studying the effects of microbial persistence and succession on a closed system during long space flight. Culture-based analyses, targeted gene-based amplicon sequencing (bacteriome, mycobiome, and resistome), and shotgun metagenomics approaches have previously been performed on ISS environmental sample sets using whole genome amplification (WGA). However, this is the first study reporting on the metagenomes sampled from ISS environmental surfaces without the use of WGA. Metagenome sequences generated from eight defined ISS environmental locations in three consecutive flights were analyzed to assess the succession and persistence of microbial communities, their antimicrobial resistance (AMR) profiles, and virulence properties. Metagenomic sequences were produced from the samples treated with propidium monoazide (PMA) to measure intact microorganisms. Results: The intact microbial communities detected in Flight 1 and Flight 2 samples were significantly more similar to each other than to Flight 3 samples. Among 318 microbial species detected, 46 species constituting 18 genera were common in all flight samples. Risk group or biosafety level 2 microorganisms that persisted among all three flights were Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, Salmonella enterica, Shigella sonnei, Staphylococcus aureus, Yersinia frederiksenii,andAspergillus lentulus.EventhoughRhodotorula and Pantoea dominated the ISS microbiome, Pantoea exhibited succession and persistence. K. pneumoniae persisted in one location (US Node 1) of all three flights and might have spread to six out of the eight locations sampled on Flight 3.
  • Annual Summary of Communicable Disease Reported to MDH, 2003

    Annual Summary of Communicable Disease Reported to MDH, 2003

    MINNESOTA DEPARTMENT OF HEALTH DISEASE CONTROL N EWSLETTER Volume 32, Number 4 (pages 33-52) July/August 2004 Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2003 Introduction Minnesota Government Data Practices do not appear in Table 2 because the Assessment is a core public health Act (Section 13.38). Provisions of the influenza surveillance system is based function. Surveillance for communi- Health Insurance Portability and on reported outbreaks rather than on cable diseases is one type of ongoing Accountability Act (HIPAA) allow for individual cases. assessment activity. Epidemiologic routine communicable disease report- surveillance is the systematic collec- ing without patient authorization. Incidence rates in this report were tion, analysis, and dissemination of calculated using disease-specific health data for the planning, implemen- Since April 1995, MDH has participated numerator data collected by MDH and a tation, and evaluation of public health as one of the Emerging Infections standardized set of denominator data programs. The Minnesota Department Program (EIP) sites funded by the derived from U.S. Census data. of Health (MDH) collects disease Centers for Disease Control and Disease incidence may be categorized surveillance information on certain Prevention (CDC) and, through this as occurring within the seven-county communicable diseases for the program, has implemented active Twin Cities metropolitan area (Twin purposes of determining disease hospital- and laboratory-based surveil- Cities metropolitan area) or outside of it impact, assessing trends in disease lance for several conditions, including (Greater Minnesota). occurrence, characterizing affected selected invasive bacterial diseases populations, prioritizing disease control and food-borne diseases. Anaplasmosis efforts, and evaluating disease preven- Human anaplasmosis (HA) is the new tion strategies.
  • Cyanide in Bronchoalveolar Lavage Is Not Diagnostic for Pseudomonas Aeruginosa in Children with Cystic Fibrosis

    Cyanide in Bronchoalveolar Lavage Is Not Diagnostic for Pseudomonas Aeruginosa in Children with Cystic Fibrosis

    Eur Respir J 2011; 37: 553–558 DOI: 10.1183/09031936.00024210 CopyrightßERS 2011 Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis M.D. Stutz*,#, C.L. Gangell*, L.J. Berry*, L.W. Garratt*, B. Sheil*,+ and P.D. Sly*,",+ on behalf of the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)1 ABSTRACT: Early detection of the cyanobacterium Pseudomonas aeruginosa in the lungs of AFFILIATIONS young children with cystic fibrosis (CF) is considered the key to delaying chronic pulmonary *Division of Clinical Sciences, Telethon Institute for Child Health disease. We investigated whether cyanide in bronchoalveolar lavage (BAL) fluid could be used as Research and Centre for Child Health an early diagnostic biomarker of infection. Research, University of Western Cyanide was measured in 226 BAL samples (36 P. aeruginosa infected) obtained from 96 infants Australia. # and young children with CF participating in an early surveillance programme involving annual School of Biological Sciences and Biotechnology, Faculty of BAL. Sustainability, Environmental and Life Cyanide was detected in 97.2% of P. aeruginosa infected and 60.5% of uninfected samples. Sciences, Murdoch University and Cyanide concentrations were significantly higher in BALs infected with P. aeruginosa (median "Dept of Respiratory Medicine, (25th–75th percentile) 27.3 (22.1–33.3) mM) than those which were not (17.2 (7.85–23.0) mM, Princess Margaret Hospital for Children, Perth, Australia. p,0.001). The best sensitivity, specificity, positive and negative predictive values were obtained +These authors shared senior author with a cut-off concentration of 20.6 mM, and were 83%, 66%, 32% and 96%, respectively.
  • Identification of Bordetella Spp. in Respiratory Specimens From

    Identification of Bordetella Spp. in Respiratory Specimens From

    504 Clinical Microbiology and Infection, Volume 14 Number 5, May 2008 isolates of extended-spectrum-beta-lactamase-producing Original Submission: 27 October 2007; Revised Sub- Shigella sonnei. Ann Trop Med Parasitol 2007; 101: 511–517. mission: 5 December 2007; Accepted: 19 December 21. Rice LB. Controlling antibiotic resistance in the ICU: 2007 different bacteria, different strategies. Cleve Clin J Med 2003; 70: 793–800. Clin Microbiol Infect 2008; 14: 504–506 22. Boyd DA, Tyler S, Christianson S et al. Complete nucleo- 10.1111/j.1469-0691.2008.01968.x tide sequence of a 92-kilobase plasmid harbouring the CTX-M-15 extended spectrum b-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Cystic fibrosis (CF) is an autosomal recessive Antimicrob Agents Chemother 2004; 48: 3758–3764. disease, characterised by defective chloride ion channels that result in multi-organ dysfunction, most notably affecting the respiratory tract. The RESEARCH NOTE alteration in the pulmonary environment is asso- ciated with increased susceptibility to bacterial infection. Recent advances in bacterial taxonomy and improved microbial identification systems Identification of Bordetella spp. in have led to an increasing recognition of the respiratory specimens from individuals diversity of bacterial species involved in CF lung with cystic fibrosis infection. Many such species are opportunistic T. Spilker, A. A. Liwienski and J. J. LiPuma human pathogens, some of which are rarely found in other human infections [1]. Processing Department of Pediatrics and Communicable of CF respiratory cultures therefore employs Diseases, University of Michigan Medical selective media and focuses on detection of School, Ann Arbor, MI, USA uncommon human pathogens.
  • Contamination of Currency Notes with Kanamycin Resistant Shigella Flexneri

    Contamination of Currency Notes with Kanamycin Resistant Shigella Flexneri

    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.07.982017; this version posted March 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Contamination of Currency Notes with Kanamycin Resistant Shigella flexneri Ebrahim Mohammed Al-Hajj1*, Malik Suliman Mohamed2,3, Noha A. Abd Alfadil4, Hisham N. Altayb5, Abeer Babiker Idris6, Salah-Eldin El-Zaki7 and Mohamed A. Hassan8,9 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan 2 Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Kingdom of Saudi Arabia 3Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan. 4 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Alneelain, Khartoum, Sudan. 5 Biochemistry department, College of sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. 6 Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan 7 Department of Epidemiology, Molecular Epidemiology Laboratory, Tropical Medicine Research Institute, Khartoum, Sudan. 8 Applied Bioinformatics Center, Africa City of Technology, Khartoum, Sudan. 9 Department of Bioinformatics, DETAGEN Genetic Diagnostics Center, Kayseri, Turkey *To whom correspondence should be addressed Ebrahim Mohammed Al-Hajj Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan.Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.07.982017; this version posted March 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • 1 Is Helicobacter Pylori Good for You?

    1 Is Helicobacter Pylori Good for You?

    University of Maryland School of Medicine A Third Century Is Helicobacter pylori Good for You? To Treat or Not to Treat, That is the Question Steven J. Czinn, M.D. Professor and Chair University of Maryland School of Medicine Department of Pediatrics Baltimore, Maryland America’s Oldest Public Medical School - USA Where Discovery Transforms Medicine Learning Objectives Disclosure • To demonstrate that H. pylori is responsible In the past 12 months, I have had no relevant for a significant portion of gastroduodenal financial relationships with the disease. manufacturer(s) of any commercial product(s) • To understand how the host immune response and/or provider(s) of commercial services contributes to Helicobacter associated discussed in this CME activity. disease. • To understand how the host immune response to Helicobacter infection might prevent asthma. • To understand which patient populations should be treated. H. pylori is an Important Human Pathogen World-Wide Prevalence of H. pylori • H. pylori is a gram negative microaerophilic bacterium that selectively colonizes the stomach. 70% 80% • It infects about 50% of the world’s population. 30% 70% 30% 50% • It is classically considered a non-invasive organism, 40% 50% 70% 70% • There is a vigorous innate and adaptive immune 70% 90% response and inflammation that is Th1 predominant 70% and includes (chronic) lymphocyte and (active) 90% 80% 80% 70% neutrophil components. 20% • Despite this response the bacterium generally persists for the life of the host. Marshall, 1995 JAMA 274:1064 1 Natural History of H. pylori infection Eradicating H. pylori Treats or Prevents: Colon Gastric cancer??? Initial infection (in childhood) Adenocarcinoma Nonulcer Chronic gastritis (universal) Dyspepsia H.
  • Increased Concentration of Iodide in Airway Secretions Is Associated with Reduced RSV Disease Severity Rachel J

    Increased Concentration of Iodide in Airway Secretions Is Associated with Reduced RSV Disease Severity Rachel J

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital Repository @ Iowa State University Veterinary Pathology Publications and Papers Veterinary Pathology 2-2014 Increased Concentration of Iodide in Airway Secretions is Associated with Reduced RSV Disease Severity Rachel J. Derscheid Iowa State University, [email protected] Albert G. van Geelen Iowa State University Abigail R. Berkebile University of Iowa Jack M. Gallup Iowa State University, [email protected] Shannon J. Hostetter IFoowlalo Swta tthie Usn iaverndsit ay,dd smitjoneions@ial wasorktates.e duat: http://lib.dr.iastate.edu/vpath_pubs Part of the Veterinary Microbiology and Immunobiology Commons, and the Veterinary See next page for additional authors Pathology and Pathobiology Commons The ompc lete bibliographic information for this item can be found at http://lib.dr.iastate.edu/ vpath_pubs/65. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Veterinary Pathology at Iowa State University Digital Repository. It has been accepted for inclusion in Veterinary Pathology Publications and Papers by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Increased Concentration of Iodide in Airway Secretions is Associated with Reduced RSV Disease Severity Abstract Recent studies have revealed that the human and nonrodent mammalian airway mucosa contains an oxidative host defense system. This three-component system consists of the hydrogen peroxide (H2O2)-producing enzymes dual oxidase (Duox)1 and Duox2, thiocyanate (SCN−), and secreted lactoperoxidase (LPO).
  • The Global View of Campylobacteriosis

    The Global View of Campylobacteriosis

    FOOD SAFETY THE GLOBAL VIEW OF CAMPYLOBACTERIOSIS REPORT OF AN EXPERT CONSULTATION UTRECHT, NETHERLANDS, 9-11 JULY 2012 THE GLOBAL VIEW OF CAMPYLOBACTERIOSIS IN COLLABORATION WITH Food and Agriculture of the United Nations THE GLOBAL VIEW OF CAMPYLOBACTERIOSIS REPORT OF EXPERT CONSULTATION UTRECHT, NETHERLANDS, 9-11 JULY 2012 IN COLLABORATION WITH Food and Agriculture of the United Nations The global view of campylobacteriosis: report of an expert consultation, Utrecht, Netherlands, 9-11 July 2012. 1. Campylobacter. 2. Campylobacter infections – epidemiology. 3. Campylobacter infections – prevention and control. 4. Cost of illness I.World Health Organization. II.Food and Agriculture Organization of the United Nations. III.World Organisation for Animal Health. ISBN 978 92 4 156460 1 _____________________________________________________ (NLM classification: WF 220) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index. html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
  • Shigella Sonnei and Shigella Flexneri

    Shigella Sonnei and Shigella Flexneri

    THE GENETICS AND EPIDEMIOLOGY OF SHIGELLA SONNEI AND SHIGELLA FLEXNERI IN VIETNAM Benjamin Robert Sobkowiak A thesis submitted for the degree of Doctorate of Philosophy Department of Genetics, Evolution and Environment University College London 1 I, Benjamin Robert Sobkowiak, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. ………………………………………………………………………………… 2 Abstract Shigella sonnei is rapidly emerging as the primary agent of bacillary dysentery, or shigellosis, in many developing countries, replacing the historically more prevalent species, S. flexneri, in these regions. There have been various theories proposed to explain this phenomenon, including environmental changes and increased antimicrobial use, though the precise reasons for this shift are still uncertain. Here I present four studies investigating key ecological and genetic differences between S. sonnei and S. flexneri from a region that has undergone this pattern of species replacement, Vietnam. This work combines experimental and bioinformatics techniques with the aim of identifying the extent that differences in disinfectant sensitivity, chromosomal antimicrobial resistance profiles and gene content will contribute to the successful spread of S. sonnei over S. flexneri. Firstly, I conducted in vitro experimental work to characterise differences between species with respect to resistance to chlorine disinfection and tolerance to the detergent SDS. The mechanisms by which the bacteria respond to this treatment, in particular the role of efflux pumps, were then explored to determine whether any informative variation in these systems will explain any differences in disinfectant sensitivity. The availability of high quality whole genome sequences for ~150 of each Shigella species allowed for robust bioinformatics work to describe genomic variation between species.
  • Summary of Notifiable Diseases — United States, 2010

    Summary of Notifiable Diseases — United States, 2010

    Morbidity and Mortality Weekly Report Weekly / Vol. 59 / No. 53 June 1, 2012 Summary of Notifiable Diseases — United States, 2010 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report CONTENTS Preface .......................................................................................................................2 TABLE 5. Reported cases and incidence* of notifiable diseases,† by Background .............................................................................................................2 race — United States, 2010 .......................................................................... 43 Infectious Diseases Designated as Notifiable at the National Level TABLE 6. Reported cases and incidence* of notifiable diseases,† by during 2010* .........................................................................................................3 ethnicity — United States, 2010 ................................................................. 45 Data Sources ...........................................................................................................4 PART 2: Graphs and Maps for Selected Notifiable Diseases Interpreting Data ...................................................................................................4 in the United States, 2010 ............................................................................. 47 Transition in NNDSS Data Collection and Reporting ................................5 PART 3: Historical Summaries
  • GRAS Notice 665, Lactoperoxidase System

    GRAS Notice 665, Lactoperoxidase System

    GRAS Notice (GRN) No. 665 http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm ORIGINAL SUBMISSION 000001 Mo•·gan Lewis Gf<N Ob()&h5 [R1~~~~~~[Q) Gary L. Yingling Senior Counsel JUL 1 8 2016 + 1.202. 739 .5610 gary.yingling@morganlewis .com OFFICE OF FOO~ ADDITIVE SAFETY July 15, 2016 VIA FEDERAL EXPRESS Dr. Antonia Mattia Director Division of Biotechnology and GRAS Notice Review Office of Food Additive Safety (HFS-200) Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740-3835 Re: GRAS Notification for the Lactoperoxidase System Dear Dr. Mattia: On behalf of Taradon Laboratory C'Taradon"), we are submitting under cover of this letter three paper copies and one eCopy of DSM's generally recognized as safe ("GRAS'') notification for its lactoperoxidase system (''LPS''). The electronic copy is provided on a virus-free CD, and is an exact copy of the paper submission. Taradon has determined through scientific procedures that its lactoperoxidase system preparation is GRAS for use as a microbial control adjunct to standard dairy processing procedures such as maintaining appropriate temperatures, pasteurization, or other antimicrobial treatments to extend the shelf life of the products. In many parts of the world, the LPS has been used to protect dairy products, particularly in remote areas where farmers are not in close proximity to the market. In the US, the LPS is intended to be used as a processing aid to extend the shelf life of avariety of dairy products, specifically fresh cheese including mozzarella and cottage cheeses, frozen dairy desserts, fermented milk, flavored milk drinks, and yogurt.